Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Almost half of patients diagnosed with pancreatic neuroendocrine tumors (PanNETs) have tumors that have spread to their liver, which correlates with poorer outcomes. Given this,
The Neuroendocrine Tumor Research Foundation celebrates a significant milestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine tumors (NETs) will
Positive results from the Phase III NETTER-2 trial were reported in September. The NETTER-2 trial is a randomized, multi-center trial evaluating whether Lutathera® plus long-acting
CEO Elyse Gellerman and Director of Patient Education Jessica Thomas joined 400 NET specialists, researchers, and patient advocates in Montreal for the NANETS 2023 Symposium.
Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide
United States Congressman Joaquin Castro (TX) joined the NET community in Austin, Texas on September 23rd and shared, for the first time publicly, his personal
NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
In December 2022, four neighborhood girls from Libertyville, Il, gathered to support cancer research for the Neuroendocrine Tumor Research Foundation with a “Cookies for Cancer”
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
